Letter to Shareholders

May 1, 2024

Dear Esteemed Shareholders:

As we embark on the fifth month of the year, I am delighted to provide you with updates on the significant developments within our organization, soon to be formally recognized as Category V Biotech, Inc.

Name Change Progress Update: We are currently in the process of submitting documents to FINRA for the name change to Category V Biotech, Inc. However, we have encountered challenges in obtaining corporate documentation dating back to 2015, as requested by FINRA. We are actively addressing this issue and are working towards securing the final two documents needed for approval from FINRA.

Despite the challenges faced in the capital markets and raising capital over the past year, our determination remains unwavering. We are committed to rebuilding and thriving, with a steadfast focus on advancing in the Cannabis Industry. Yesterday marked a pivotal moment for the industry as the DEA has finally agreed to reschedule Cannabis. This reclassification will reinvigorate investment in the Cannabis Industry to levels previously observed.

Exciting News on Marijuana Policy Reform: I am thrilled to share the recent developments in marijuana policy that could have significant implications for Category V Biotech, Inc.  The U.S. Drug Enforcement Administration (DEA) announced that it will reclassify marijuana as a less dangerous drug from Schedule I to Schedule III, marking a historic shift in American drug policy.

The proposal, pending review by the White House Office of Management and Budget, would recognize the medical uses of cannabis and acknowledge its lower potential for abuse compared to some of the nation’s most dangerous drugs. While this development does not legalize marijuana outright for recreational use, it represents a monumental step towards reforming outdated drug policies.

The immediate impact of this rescheduling opens up new opportunities for research and development within the cannabis industry, new capital into the Cannabis space, and a better Return on Investment for current and future shareholders. Easing federal regulations could reduce tax burdens for businesses like ours and facilitate authorized clinical studies on marijuana, which have been challenging under current restrictions.

One of the biggest benefits of cannabis rescheduling is that Internal Revenue Code 280E will no longer apply to state-licensed cannabis businesses. However, that impact will not manifest unless and until the DEA adopts its final cannabis rescheduling rule. When it’s ultimately implemented, it will mean that marijuana firms can officially take federal tax deductions that they’ve been barred from under an Internal Revenue Service (IRS) code known as 280E.  This means more profit to the bottom line which in turn means investors stand to make more ROI on their capital.

Attorney General Merrick Garland's endorsement of this proposal underscores its importance to the Biden administration. President Biden has been vocal about the need to review federal marijuana law, aligning with efforts to address the criminalization of marijuana possession and use. This announcement coincides with a growing bipartisan push for marijuana reform, reflecting shifting attitudes towards cannabis legalization nationwide.

Future Strategies and Predictions: Recognizing the financial challenges associated with our company’s capital requirements, we assure you of our proactive efforts to explore avenues for raising capital and acquiring companies. With the reclassification of Cannabis to Controlled Substance III, we expect the capital markets to resume investing in Cannabis companies.

The forthcoming release of our first quarter, 2024 financials, will provide a comprehensive overview of our financial situation, demonstrating our commitment to transparency and ensuring that you are well informed.

Thank you for your indispensable role in the journey towards Category V Biotech, Inc.

Sincerely,

Michael Feldenkrais Chief Executive Officer 4Cable TV International, Inc. (soon to be Category V Biotech, Inc.)